EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY 4.0

Patient, Physician, and Assessor Blinding in Phase III Randomized Trials in Oncology: A Meta‐Epidemiological Analysis

Gabrielle Brown, Pavlos Msaouel, Avital M Miller iD, Ramez Kouzy, Timothy A Lin, Joseph Abi Jaoude iD, Ethan B Ludmir iD, Alexander D Sherry iD

Cancer Medicine · 2025

DOI: 10.1002/cam4.71097 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Cancer Medicine, 2025. Verfasst von Gabrielle Brown und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Radiation Oncology, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Clinical Trials, Phase III as Topic, Randomized Controlled Trials as Topic, Neoplasms, Medical Oncology. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Andrew Sabin Family Foundation, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Blinding mitigates bias in randomized trials and may be especially crucial for surrogate endpoints, such as progression‐free survival (PFS). Here, we characterize utilization of and factors associated with blinding in Phase III oncology trials with PFS primary endpoints.

Methods

Two‐arm, superiority‐design trials investigating systemic therapy were identified in May 2024 from ClinicalTrials.gov with no date limitation. Trials were required to have a PFS primary endpoint. The study outcomes were the presence of double‐blind designs and blinded independent central review (BICR) for the primary endpoint. Ninety‐five percent credible intervals for binary outcomes were estimated from beta distributions, and multivariable logistic regressions explored associations with trial‐level features.

Results

After screening, 237 trials were included, enrolling 127,518 patients. A double‐blind design was used in 105 trials (44%, 95% CrI 38%–51%). BICR was used in 111 trials (47%, 95% CrI 41%–53%), including 39 double‐blind trials (16%, 95% CrI 12%–22%). Trials with BICR had higher odds of meeting the primary endpoint (OR 1.84; 95% CI 1.06–3.18; p = 0.03). The PFS assessor identity (central vs. local) or blinding status was not reported in 50 trials (26%, 95% CrI 16%–27%). Trials that met prespecified significance criteria for PFS were more likely to report whether PFS assessors were blinded/unblinded and central/local (OR, 3.05; 95% Cl: 1.60–5.81; p = 0.0007).

Conclusions

Despite the importance of double blinding in combination with BICR for reducing bias, only a few trials blinded physicians, patients, and primary endpoint assessors. This meta‐epidemiological study illuminates the prevalence of potential assessment biases affecting PFS in Phase III oncology and secondarily emphasizes the need for improved methodology reporting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials, Phase III as TopicRandomized Controlled Trials as TopicNeoplasmsMedical OncologyHumansDouble-Blind MethodProgression-Free SurvivalResearch DesignPhysicians

Stichwörter der Autor:innen

Phase IIIbiasblinded independent central reviewdouble‐blindoncologyrandomized trials

Autor:innen und Institutionen

  • Division of Radiation Oncology, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Division of Cancer Medicine, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Division of Pathology and Laboratory Medicine, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Radiation Oncology, Stanford University, Stanford, California, USA.
  • Division of Radiation Oncology, Department of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Avital M Miller, Joseph Abi Jaoude, Ethan B Ludmir, Alexander D Sherry

Förderung

  • NCI NIH HHS
  • Andrew Sabin Family Foundation
  • National Cancer Institute

Zitieren

APA

Brown, G., Msaouel, P., Miller, A. M., Kouzy, R., Lin, T. A., Abi Jaoude, J., Ludmir, E. B., & Sherry, A. D. (2025). Patient, Physician, and Assessor Blinding in Phase III Randomized Trials in Oncology: A Meta‐Epidemiological Analysis. Cancer Medicine. https://doi.org/10.1002/cam4.71097

Vancouver

Brown G, Msaouel P, Miller AM, Kouzy R, Lin TA, Abi Jaoude J, et al. Patient, Physician, and Assessor Blinding in Phase III Randomized Trials in Oncology: A Meta‐Epidemiological Analysis. Cancer Medicine. 2025. doi:10.1002/cam4.71097

BibTeX
@article{Brown2025,
  author = {Brown, Gabrielle and Msaouel, Pavlos and Miller, Avital M and Kouzy, Ramez and Lin, Timothy A and Abi Jaoude, Joseph and Ludmir, Ethan B and Sherry, Alexander D},
  title = {Patient, Physician, and Assessor Blinding in Phase III Randomized Trials in Oncology: A Meta‐Epidemiological Analysis},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71097}
}
Kostenlos starten →